Will US saying to China that saving lives at substantially lower cost considered excess capacity to ban it in America to protect pharmaceutical giants exorbitant profits in the process? SCMP: A decade ago, treating cancer with personalised mRNA vaccines seemed like a US$1 million gamble per patient, a therapy reserved for the ultra-rich. But Chinese biotech start-ups are aiming to change that – by designing cancer therapy for a fraction of the cost. 美國是否會說，以極低的成本挽救生命被視為產能過剩，從而在美國禁止該藥物，以保護製藥巨頭在這過程中的暴利？ 《南華早報》：十年前，使用個人化 mRNA 疫苗治療癌症似乎是每位患者100萬美元的賭注，而這種療法只有超級富豪才能享受。但中國生技新創公司正致力於改變這一現狀, 以極低的成本設計癌症治療方法.